New Delhi. Shares of Specialty Medicines Limited, a company working in the pharmaceutical sector, made a flat entry in the stock market today. However, IPO investors made slight profits as purchases started after listing. Under the IPO, the company’s shares were issued at a price of Rs 124. Today its listing on the SME platform of BSE remained at the level of Rs 124 without any change.
After the listing, buyers created buying pressure, due to which the share jumped to the level of Rs 129.50. However, after this selling started, due to which the movement of this stock declined. After trading till 11:15 pm, the shares of the company were trading at the level of Rs 124.50. Thus, after the trading till now, the IPO investors of the company were in profit of fifty paise per share i.e. 0.40 percent.
The Rs 29.14 crore IPO of Specialty Medicines Limited was open for subscription between March 20 and 24. This IPO received an average response from investors, due to which it was subscribed 2.27 times overall. Of these, the reserve portion for Qualified Institutional Buyers (QIB) was subscribed 96.24 times. Whereas the reserve portion for Non-Institutional Investors (NII) received 1.88 times subscription. Similarly, the reserve portion for retail investors could be subscribed only 0.85 times.
Under this IPO, 23.50 lakh new shares with face value of Rs 10 have been issued. The company will use the money raised through the IPO to set up its R&D centre, develop products for the overseas market, market and promote its products, meet working capital needs and for general corporate purposes.
Talking about the financial condition of the company, as per the claim made in the Draft Red Herring Prospectus (DRHP) submitted to the capital market regulator SEBI, its financial health has continuously strengthened. In the financial year 2023-24, the company had a net profit of Rs 2.93 crore, which increased to the level of Rs 8.61 crore in the next financial year 2024-25. In the current financial year from April to October 31, 2025, the company has made a net profit of Rs 6.06 crore.
During this period, the company’s revenue also increased continuously. In the financial year 2023-24, it received a total revenue of Rs 27.66 crore, which increased to Rs 58.54 crore in the financial year 2024-25. In the current financial year from April to October 31, 2025, the company has received a revenue of Rs 36.93 crore.
During this period, the debt burden on the company also increased. At the end of the financial year 2023-24, the company had a debt of Rs 2.86 crore, which increased to Rs 5.05 crore in the financial year 2024-25. In the current financial year from April to October 31, 2025, the company had a debt of Rs 4.81 crore.
The company’s net worth also increased during this period. In the financial year 2023-24, the net worth of the company was at the level of Rs 15.06 crore, which increased to the level of Rs 23.98 crore in 2024-25. In the current financial year, from April to October 31, 2025, the company’s net worth jumped to the level of Rs 30.04 crore.
Similarly, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization) was at the level of Rs 5.26 crore in 2023-24, which increased to Rs 9.09 crore in 2024-25. Whereas in the current financial year from April to October 31, 2025, the company’s EBITDA was at the level of Rs 6.51 crore.
Comments are closed.